Parenteral anticoagulants associated with lower risk in COVID-19
Chinese study found a composite outcome was significantly better in those on the therapy
AusDoc brings you the latest news from the European Society of Cardiology Congress 2020.
A study of 1125 patients admitted to hospital with COVID-19 in Wuhan shows that use of anticoagulants, particularly administered parenterally, gave better outcomes.
The study investigating thromboembolism, major bleeding and mortality in relation to underlying risk factors and anticoagulation use was presented at the European Society of Cardiology’s virtual conference (ESC 2020) this week.
The mean age of participants in the study was 58 years and half were men. They were followed for a mean of 21 days, Professor Yutao Guo, of the Chinese PLA General Hospital in Wuhan, China, told delegates.
